Elafibranor (also known as GFT505), which is a dual-PPARα/δ agonist, has shown a potent ameliorative effect on insulin resistance, hyperglycemia and dyslipidemia in obese patients with impaired glucose tolerance without significant safety concern [72,73]. Here, PPARA is linked to metabolic syndrome.